We have recently identified the pathogenic impact of identified NFKB1 deleterious variants in our PAD cohort; we have shown that missense mutation in the NFKB1 causes late-onset PAD by impairing the function of the transcriptionally active p50 (10). This evidence concerns the gene NFKB1 and peripheral arterial disease.